WO2015199192A1 - Promoteur de la sécrétion de ghréline - Google Patents

Promoteur de la sécrétion de ghréline Download PDF

Info

Publication number
WO2015199192A1
WO2015199192A1 PCT/JP2015/068398 JP2015068398W WO2015199192A1 WO 2015199192 A1 WO2015199192 A1 WO 2015199192A1 JP 2015068398 W JP2015068398 W JP 2015068398W WO 2015199192 A1 WO2015199192 A1 WO 2015199192A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
ghrelin
secretion promoter
promoter according
ghrelin secretion
Prior art date
Application number
PCT/JP2015/068398
Other languages
English (en)
Japanese (ja)
Inventor
中村　健太郎
健人 山地
秋菜 笹山
秀和 殿内
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Priority to CN201580030841.XA priority Critical patent/CN106535915B/zh
Priority to SG11201610051YA priority patent/SG11201610051YA/en
Priority to JP2016529658A priority patent/JP6657084B2/ja
Publication of WO2015199192A1 publication Critical patent/WO2015199192A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Definitions

  • Such a blending amount is particularly preferable when the phospholipid is milk phospholipid.
  • Suitable examples of the blending ratio of the polyunsaturated fatty acid to the total fatty acid in the agent of the present invention are 25% by weight or more, 25 to 90% by weight, 25 to 80% by weight, 25 to 70% by weight, 30 to 70% by weight. % Or 30 to 60% by weight. Further, in another suitable example of the blending ratio of the polyunsaturated fatty acid, 10 wt% or more, 10 wt% to 70 wt%, 10 wt% to 60 wt%, 10 wt% to 50 wt%, 10 wt% -40 wt%, 10 wt% to 30 wt%, 15 wt% to 30 wt%, or 15 wt% to 20 wt%.
  • palatinose As a raw material for the carbohydrate of the present invention, Sugar alcohols (sorbitol, xylitol, maltitol) can also be used instead of or in combination with palatinose.
  • sugar alcohols sorbitol, xylitol, maltitol
  • these raw materials for example, in the case of palatinose, commercially available palatinose raw materials such as commercially available palatinose syrup, reduced palatinose, palatinose syrup and the like can be used.
  • a composition containing a protein hydrolyzate and a fermented milk protein as a protein; a medium chain fatty acid as a lipid; and a saccharide in the manufacture of a ghrelin secretion promoter in the manufacture of a ghrelin secretion promoter.
  • a composition containing a protein hydrolyzate and a fermented milk protein as a protein; a medium chain fatty acid as a lipid; and a saccharide for a ghrelin secretion promoter is provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention se rapporte à un nouveau promoteur de la sécrétion de ghréline et, plus spécifiquement, à un promoteur de la sécrétion de ghréline comprenant: un hydrolysat de protéine et une protéine de lait fermenté comme protéines; un acide gras à chaîne moyenne comme lipide; et un saccharide.
PCT/JP2015/068398 2014-06-25 2015-06-25 Promoteur de la sécrétion de ghréline WO2015199192A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201580030841.XA CN106535915B (zh) 2014-06-25 2015-06-25 生长素释放肽分泌促进剂
SG11201610051YA SG11201610051YA (en) 2014-06-25 2015-06-25 Ghrelin secretion promoter
JP2016529658A JP6657084B2 (ja) 2014-06-25 2015-06-25 グレリン分泌促進剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014-130143 2014-06-25
JP2014130143 2014-06-25

Publications (1)

Publication Number Publication Date
WO2015199192A1 true WO2015199192A1 (fr) 2015-12-30

Family

ID=54938269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/068398 WO2015199192A1 (fr) 2014-06-25 2015-06-25 Promoteur de la sécrétion de ghréline

Country Status (5)

Country Link
JP (1) JP6657084B2 (fr)
CN (1) CN106535915B (fr)
SG (1) SG11201610051YA (fr)
TW (1) TWI726846B (fr)
WO (1) WO2015199192A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018012578A1 (fr) * 2016-07-14 2018-01-18 株式会社明治 Promoteur de sécrétion de ghréline
JP2018027925A (ja) * 2016-08-19 2018-02-22 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
JP2018085965A (ja) * 2016-11-29 2018-06-07 花王株式会社 乳飲料
JP2019048849A (ja) * 2018-11-14 2019-03-28 株式会社明治 グレリン分泌促進剤
JP2020083852A (ja) * 2018-11-30 2020-06-04 株式会社明治 ストレス性疾患予防組成物
WO2022191184A1 (fr) * 2021-03-08 2022-09-15 国立大学法人九州大学 Agent d'amélioration de la sensibilité du récepteur de ghréline, composition d'amélioration de la sensibilité du récepteur de ghréline et procédé d'activation du récepteur de ghréline

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008111573A1 (fr) * 2007-03-12 2008-09-18 Snow Brand Milk Products Co., Ltd. Stimulateur de sécrétion d'hormone de croissance
WO2011065552A1 (fr) * 2009-11-30 2011-06-03 明治乳業株式会社 Composition nutritionnelle bénéfique pour l'intestin grêle
JP2013227309A (ja) * 2012-03-30 2013-11-07 Ajinomoto Co Inc グレリン分泌促進剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008111573A1 (fr) * 2007-03-12 2008-09-18 Snow Brand Milk Products Co., Ltd. Stimulateur de sécrétion d'hormone de croissance
WO2011065552A1 (fr) * 2009-11-30 2011-06-03 明治乳業株式会社 Composition nutritionnelle bénéfique pour l'intestin grêle
JP2013227309A (ja) * 2012-03-30 2013-11-07 Ajinomoto Co Inc グレリン分泌促進剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKIHIRO ASAKAWA: "Title 3 Rikkunshito to Ghrelin Signal", MEDICAMENT NEWS, 25 January 2013 (2013-01-25), pages 19 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018012578A1 (fr) * 2016-07-14 2018-01-18 株式会社明治 Promoteur de sécrétion de ghréline
JP2018008901A (ja) * 2016-07-14 2018-01-18 株式会社明治 グレリン分泌促進剤
CN109715180A (zh) * 2016-07-14 2019-05-03 株式会社明治 饥饿素分泌促进剂
JP2018027925A (ja) * 2016-08-19 2018-02-22 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
WO2018034345A1 (fr) * 2016-08-19 2018-02-22 株式会社明治 Composition permettant d'améliorer la neuropathie périphérique provoquée par des agents anticancéreux
JP2018085965A (ja) * 2016-11-29 2018-06-07 花王株式会社 乳飲料
JP2019048849A (ja) * 2018-11-14 2019-03-28 株式会社明治 グレリン分泌促進剤
JP2020083852A (ja) * 2018-11-30 2020-06-04 株式会社明治 ストレス性疾患予防組成物
WO2022191184A1 (fr) * 2021-03-08 2022-09-15 国立大学法人九州大学 Agent d'amélioration de la sensibilité du récepteur de ghréline, composition d'amélioration de la sensibilité du récepteur de ghréline et procédé d'activation du récepteur de ghréline

Also Published As

Publication number Publication date
CN106535915B (zh) 2020-09-29
TW201613631A (en) 2016-04-16
SG11201610051YA (en) 2017-01-27
TWI726846B (zh) 2021-05-11
JPWO2015199192A1 (ja) 2017-06-08
CN106535915A (zh) 2017-03-22
JP6657084B2 (ja) 2020-03-04

Similar Documents

Publication Publication Date Title
JP6657084B2 (ja) グレリン分泌促進剤
JP5688818B2 (ja) 栄養組成物
JP6234227B2 (ja) 腸内菌叢改善用栄養組成物
Walzem et al. Whey components: millennia of evolution create functionalities for mammalian nutrition: what we know and what we may be overlooking
Park Bioactive components in goat milk
EP1976397B1 (fr) Preparations immunologiques destinees aux nourrissons
Korhonen Bioactive components in bovine milk
BRPI0608782A2 (pt) fórmula para bebê com probióticos
CN112823667B (zh) 组合物在预防或缓解婴幼儿肠绞痛中的应用
TWI629994B (zh) 包括乳鐵蛋白之營養組成物於刺激免疫細胞上之用途
JP2016531114A (ja) 腫瘍の成長を阻止する栄養組成物
MX2014004061A (es) Composiciones nutricionales de suero-caseina parcialmente hidrolizadas para reducir la aparicion de alergias.
JP5025491B2 (ja) 抗炎症組成物および抗炎症組成物の製造法
JP5797234B2 (ja) 新規消炎鎮痛剤
JP6773562B2 (ja) スフィンゴ脂質吸収促進剤
TWI754662B (zh) 改善抗癌劑所引起之末梢神經損害用之組成物
Miralles et al. Health-related functional value of dairy proteins and peptides
JPH10262607A (ja) 乳幼児用栄養組成物
Kumar et al. Bioactive and functional ingredients from dairy products
JP7383874B2 (ja) エンドトキシンの血中移行阻害用組成物
TW201822640A (zh) 包含麥芽三糖之組成物，及使用彼以抑制由脫水方法導致之傷害的方法
Park Bioactive components in cow's milk
AU2003283831B2 (en) Nutritional compositions
Low Immunomodulatory properties of bovine whey proteins and whey protein concentrates: a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Nutritional Science and Immunology at Massey University, Palmerston North, New Zealand
Upadhay et al. In Touch

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15812469

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016529658

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15812469

Country of ref document: EP

Kind code of ref document: A1